Mutual of America Capital Management LLC Has $8.16 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mutual of America Capital Management LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 79.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,430 shares of the company's stock after purchasing an additional 8,609 shares during the quarter. Mutual of America Capital Management LLC's holdings in IDEXX Laboratories were worth $8,160,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 3,766.7% during the 1st quarter. Golden State Wealth Management LLC now owns 116 shares of the company's stock worth $49,000 after buying an additional 113 shares during the period. Sagespring Wealth Partners LLC bought a new position in IDEXX Laboratories in the 1st quarter valued at about $229,000. Banque Transatlantique SA acquired a new stake in IDEXX Laboratories during the fourth quarter worth approximately $2,681,000. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of IDEXX Laboratories by 13.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 25,553 shares of the company's stock worth $10,731,000 after acquiring an additional 2,931 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of IDEXX Laboratories by 42.7% in the first quarter. GAMMA Investing LLC now owns 2,187 shares of the company's stock valued at $918,000 after purchasing an additional 654 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director owned 1,801 shares of the company's stock, valued at approximately $922,724.34. This represents a 41.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.98% of the company's stock.

Analyst Ratings Changes

IDXX has been the topic of a number of research reports. Morgan Stanley set a $722.00 price objective on IDEXX Laboratories and gave the company an "overweight" rating in a report on Tuesday. Leerink Partners upped their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Stifel Nicolaus set a $640.00 price target on shares of IDEXX Laboratories in a research report on Monday. BTIG Research boosted their price objective on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a report on Tuesday. Finally, JPMorgan Chase & Co. increased their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a research report on Monday. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $623.56.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock traded up $25.87 on Thursday, reaching $650.06. 798,751 shares of the stock were exchanged, compared to its average volume of 789,096. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.11. The firm has a market cap of $52.00 billion, a PE ratio of 54.13, a P/E/G ratio of 4.03 and a beta of 1.49. The firm's 50 day moving average is $542.32 and its 200-day moving average is $477.73. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company posted $2.44 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.